Patents by Inventor Christopher Parish
Christopher Parish has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230255992Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRO). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g.Type: ApplicationFiled: February 6, 2023Publication date: August 17, 2023Applicants: The Australian National University, Griffith UniversityInventors: Christopher Parish, Connor O'Meara, Lucy Coupland, Benjamin Ju Chye Quah, Farzaneh Kordbacheh, Anna Orlov, Anna Browne, Ross Stephens, Gregory David Tredwell, Lee Andrew Philip, Karen Knox, Laurence Mark von Itzstein, Chih-Wei Chang, Anne Brüstle, David Anak Simon Davis
-
Patent number: 11628179Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Type: GrantFiled: December 14, 2018Date of Patent: April 18, 2023Assignees: The Australian National University, Griffith UniversityInventors: Christopher Parish, Connor O'Meara, Lucy Coupland, Benjamin Ju Chye Quah, Farzaneh Kordbacheh, Anna Orlov, Anna Browne, Ross Stephens, Gregory David Tredwell, Lee Andrew Philip, Karen Knox, Laurence Mark von Itzstein, Chih-Wei Chang, Anne Brüstle, David Anak Simon Davis
-
Publication number: 20220168327Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Type: ApplicationFiled: February 25, 2019Publication date: June 2, 2022Inventors: Christopher Parish, Connor O'Meara, Lucy Coupland, Benjamin Ju Chye Quah, Farzaneh Kordbacheh, Anna Bezos, Anna Browne, Ross Stephens, Gregory David Tredwell, Lee Andrew Philip, Karen Knox, Laurence Mark von Itzstein, Chih-Wei Chang, Anne Brüstle, David Anak Simon Davis
-
Publication number: 20210205343Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Type: ApplicationFiled: December 14, 2018Publication date: July 8, 2021Inventors: Christopher Parish, Connor O'Meara, Lucy Coupland, Benjamin Ju Chye Quah, Farzaneh Kordbacheh, Anna Bezos, Anna Browne, Ross Stephens, Gregory David Tredwell, Lee Andrew Philip, Karen Knox, Laurence Mark von Itzstein, Chih-Wei Chang, Anne Brüstle, David Anak Simon Davis
-
Patent number: 10507236Abstract: The present invention is directed generally to chimeric proteins that can facilitate targeting of nanoparticulate carriers to antigen presenting cells, and to nanoparticulate carriers comprising these chimeric proteins. The invention is also directed to methods of internalizing an antigen in an antigen presenting cell, and methods of eliciting an immune response to an antigen in a subject, using the nanoparticulate carriers comprising the chimeric proteins.Type: GrantFiled: October 9, 2015Date of Patent: December 17, 2019Assignees: Lipotek Pty Ltd, The Australian National UniversityInventors: Jason David Price, Christopher Parish, Ines Atmosukarto
-
Publication number: 20180185464Abstract: The present invention is directed generally to chimeric proteins that can facilitate targeting of nanoparticulate carriers to antigen presenting cells, and to nanoparticulate carriers comprising these chimeric proteins. The invention is also directed to methods of internalising an antigen in an antigen presenting cell, and methods of eliciting an immune response to an antigen in a subject, using the nanoparticulate carriers comprising the chimeric proteins.Type: ApplicationFiled: October 9, 2015Publication date: July 5, 2018Inventors: Jason David Price, Christopher Parish, Ines Atmosukarto
-
Publication number: 20140341971Abstract: The present invention relates to a composition for targeting dendritic cells. In particular, the present invention relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The invention further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.Type: ApplicationFiled: June 20, 2014Publication date: November 20, 2014Applicants: LIPOTEK PTY LTD, DOMANTIS LIMITEDInventors: Joseph ALTIN, Ines Atmosukarto, Rudolf Maria De Wildt, Christopher Parish, Jason Price
-
Patent number: 8779107Abstract: The present disclosure relates to a composition for targeting dendritic cells. In particular, the present disclosure relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The disclosure further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.Type: GrantFiled: October 19, 2009Date of Patent: July 15, 2014Assignees: Lipotek Pty Ltd, Domantis LimitedInventors: Joseph Altin, Ines Atmosukarto, Rudolf Maria De Wildt, Christopher Parish, Jason Price
-
Publication number: 20110212168Abstract: The present disclosure relates to a composition for targeting dendritic cells. In particular, the present disclosure relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The disclosure further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.Type: ApplicationFiled: October 19, 2009Publication date: September 1, 2011Inventors: Joseph Altin, Ines Atmosukarto, Rudolf Maria De Wildt, Christopher Parish, Jason Price
-
Publication number: 20080038281Abstract: The present invention relates generally to modifying biological and/or synthetic membranes or liposomes, or combinations thereof, for the purpose of altering immunity, or for the targeting of drugs and other agents to a specific cell type or tissue when administered in vivo to achieve a therapeutic effect. Modification of the membranes is achieved by incorporation and/or attachment of metal chelating groups, thereby allowing engraftment of one or more targeting molecules possessing a metal affinity tag, and a targeting of the engrafted membranes to specific cell types or tissues in vivo.Type: ApplicationFiled: March 20, 2007Publication date: February 14, 2008Inventors: Joseph Altin, Christopher Parish
-
Publication number: 20070026057Abstract: The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the dendritic cells, the ligand being linked to a metal chelating group via a metal affinity tag on the ligand. The composition further includes an immunomodulatory factor. A process for preparing the composition is also provided. The invention further provides a method of modulating an immune disorder, and methods of treating tumours and infections.Type: ApplicationFiled: August 23, 2004Publication date: February 1, 2007Applicant: LIPOTEK PTY LTD.Inventors: Joseph Altin, Christopher Parish
-
Publication number: 20050003358Abstract: Provided are novel cancer markers for the diagnosis of cancer in humans and non-human mammalian subjects, specifically a cancer marker comprising a negatively-charged molecule with a mass/charge (m/z) ratio of about 991. The cancer marker of the invention may be used to determine the presence of one or more cancerous cells or tumors in a biological sample by assaying the sample for a reduced level of said cancer marker.Type: ApplicationFiled: August 5, 2002Publication date: January 6, 2005Inventors: Christopher Parish, Vivian Cabalda-Crane
-
Publication number: 20040029194Abstract: The present invention provides a mass spectrometry-based method of identifying a cancer marker in sera and uses of said cancer marker in diagnosing cancer in human and non-human subjects. The invention further provides isolated cancer markers.Type: ApplicationFiled: August 20, 2003Publication date: February 12, 2004Inventors: Christopher Parish, Vivian Mae Cabalda-Crane